-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 16, the official website of the State Food and Drug Administration revealed that Yangtze River Shanghai Haini Pharmaceutical's Milrinone injection was approved as a supplementary application, making it the third company to have reviewed the product
July 16, 2021 Drug Approval Documents Pending Information Release
Data show that milrinone is a phosphodiesterase inhibitor cardiotonic drug, which has the effect of dilating vascular smooth muscle, can reduce the load on the heart, and can also improve the blood supply of the kidneys and muscles.
The sales of milrinone injection at the terminal of China's public medical institutions in recent years (unit: 100 million yuan)
Source: Terminal competition landscape of China's public medical institutions
Milrinone injection was developed by Sanofi-Aventis.
Source: One-click search on Mi Nei.
In terms of consistency evaluation, prior to this, only Nanjing Jianyou Biochemical Pharmaceuticals and Shanghai Xudong Haipu Pharmaceuticals were approved for generic 4 types of this product, which are deemed to have been reviewed
Source: official website of the State Food and Drug Administration, Mi Nei.
